Multi-omics data integration to identify metabolism pathways and therapeutic targets for

cardiac disease

Authors and affiliations

Sophie C. de Ruiter, MSc [1], Marion van Vugt, MSc [2, 3, 4], Chris Finan, PhD [3, 4, 5, 6], Rui Providencia,

MD PhD [6, 7], Sandesh Chopade, MSc [3, 5], Diederick E. Grobbee, PhD [1], Hester M. den Ruijter, PhD [8],

Sanne A.E. Peters, PhD [1, 9, *], A. Floriaan Schmidt, PhD [2, 3, 4, 5, *]

1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,

Utrecht University, Utrecht, the Netherlands

2. Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University

Medical Centres, University of Amsterdam, Amsterdam, the Netherlands

3. Institute of Cardiovascular Science, Faculty of Population Health, University College

London, London, United Kingdom

4. Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht,

Utrecht University, Utrecht, the Netherlands

5. UCL British Heart Foundation Research Accelerator, London, United Kingdom

6. Health Data Research UK and Institute of Health Informatics, University College London,

London, United Kingdom

7. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, United

Kingdom

8. Laboratory of Experimental Cardiology, Division Heart and Lungs, University Medical

Center Utrecht, Utrecht University, Utrecht, the Netherlands

9. The George Institute for Global Health, School of Public Health, Imperial College

London, London, UK

* joint senior author

Running title: Therapeutic targets and metabolic pathways for cardiac disease

Word count text: 4460

Word count abstract: 257

Number of references: 54

Number of tables and figures: 7

Number of (web) appendices: 2

Abstract

Introduction: Urinary breakdown products, representing kidney regulated filtration of metabolism

end products, contain cardiac disease biomarkers such as NT-proBNP. We set out to integrate plasma

proteins with metabolism pathways, as reflected by urinary breakdown products, to identify

potentially druggable metabolism pathways for cardiac disease.

Methods: Data was leveraged from a genome-wide association study (GWAS) on 954 urinary

breakdown products. Mendelian randomisation was used to identify urinary breakdown products

associating with atrial fibrillation (AF), heart failure (HF), dilated cardiomyopathy (DCM), or

hypertrophic cardiomyopathy (HCM). By interrogating eight independent plasma protein GWAS,

jointly including 92,277 participants and 1,562 unique proteins, we identified druggable plasma

proteins with a directionally concordant effect on urinary breakdown products and cardiac outcomes.

Results: In total, 38 unique urinary breakdown products associated with cardiac disease,

predominantly covering breakdown products from amino acid metabolism (n=12), xenobiotic

metabolism (n=5), and unclassified metabolism origins (n=16). Subsequently, we identified 32

druggable proteins expressed in cardiac tissue, which had a directionally concordant association with

the identified urinary breakdown products and cardiac outcomes. This included positive control

findings, for example higher values of AT1B2 (targeted by digoxin) decreased the risk of HCM, which

we were able to link to a novel unclassified urinary breakdown product (X-15497). Additionally, we

showed that increased plasma RET values, a mediator of GDF-15 signalling, reduced the risk of HF,

and linked this to the novel unclassified urinary breakdown product X-23776.

Conclusion: We have identified amino acid, xenobiotic and unclassified metabolism as important

pathways contributing to cardiac disease and prioritised 32 druggable proteins as potential therapeutic

targets.

Introduction

Heart failure (HF) and atrial fibrillation (AF) are cardiac diseases which manifest as ventricular and

atrial dysfunction, respectively. While AF frequently affects people without established HF, in people

with HF an AF diagnosis often signals early progressive HF, where ventricular disfunction has an

early knock-on effect on atrial rhythm and output. People with hypertrophic cardiomyopathies (HCM),

a subtype of HF characterized by an abnormally large and stiff cardiac septum, which may limit

cardiac output and affect diastolic function, are particularly susceptible to develop AF. Aside from

HCM, dilated cardiomyopathy (DCM) represents a second major non-ischemic HF subtype, where the

left ventricle becomes enlarged and thin, limiting cardiac contractility. As such, AF and HF are closely

interrelated diseases, with specific underlying pathologies like HCM and DCM playing distinct roles

in their manifestation.

Aside from N-terminal prohormone of brain natriuretic peptide (NT-proBNP), which associates with

HF and AF progression(1-3), there is paucity of biomarkers to assist medical practitioners in tailored

treatment management, diagnosis, and prognosis. NT-proBNP, which is secreted by cardiomyocytes

(cardiac cells responsible for contraction), can be measured in both blood plasma and urine,

illustrating the interface between cardiac tissue processes, blood, and urine. Urine biomarkers provide

a non-invasive measurement of potential causal metabolic changes reflecting disease onset and

progression. While urinary breakdown products represent by-products cleared from plasma, the source

of these breakdown products may reflect pathophysiological changes in tissues such as the cardiac

muscle. Cardiac function and kidney function are intertwined, through for example the renin-

angiotensin-aldosterone system, and the concept of cardiorenal syndrome has been implemented to

describe disorders involving both organs, with dysfunction in one organ causing acute or chronic

dysfunction in the other(4, 5). Urinary breakdown products are therefore a potentially important

source of non-invasive disease markers, which may unveil upstream involvement of biological

pathways relevant for cardiac progression and/or novel cardiac therapeutics.

Recently, availability of affordable, high-throughput assays capable of measuring hundreds of proteins

and metabolites has facilitated their analysis in large sample size genome wide association studies

(GWAS). Given that proteins form the main constituents of drug targets, GWAS on protein values

provide an invaluable resource to identify potential drug targets through genomics tools such as

Mendelian randomisation (MR). Utilizing MR, one can infer the effect of an exposure (e.g. a

breakdown product or protein) on the risk of disease, by identifying genetic variants strongly

associated with the exposure, and determining whether there is a dose-response relationship between

the genetic associations with the exposure and the genetic associations with disease(6, 7). Given that

genetic variants are fixed at gametogenesis, genetic evidence is robust against bias due to confounding

or reverse causation(8, 9). These principles have been extensively validated in the context of

cardiovascular disease(10-13), including in a recent study on the effects of plasma proteins on cardiac

function and structure(14).

Although urinary breakdown products are important markers of potential disease mechanisms, they

are not directly actionable because they have already been excreted. Plasma proteins are however still

actionable and are the main constituents of drug targets. Therefore, we integrated information from

urinary metabolism breakdown products to identify metabolism pathways relevant for cardiac disease

and information from plasma proteins to identify drug targets that may be used to intervene in these

pathways.

In the current manuscript we used MR to analyse urinary metabolism breakdown products to identify

metabolism pathways with possible involvement with four cardiac disease traits: AF, HF, DCM, and

HCM. Subsequently, we sought to establish potential plasma protein intermediates by identifying

proteins associating with urinary breakdown product values, as well as with cardiac disease risk. The

Human Protein Atlas (HPA) was consulted to identify proteins expressed in cardiac tissue, providing

further support for cardiac involvement. The subset of proteins expressed in cardiac tissue were

subsequently mapped to biological pathways, with druggability determined through linkage with

ChEMBL.

Methods

Available data

We used a GWAS on 954 urinary breakdown products, which were identified and quantified among

1,627 individuals using a non-targeted mass spectrometry assay provided by Metabolon(15). This

untargeted approach allows for comprehensive detection of breakdown products, including those of

unknown origin. Breakdown products were categorised based on the metabolic origin of the urinary

breakdown products: amino acids, carbohydrates, cofactors and vitamins, energy, lipids, nucleotides,

peptides, xenobiotics, and unclassified. Xenobiotic breakdown products - substances not naturally

produced by the human body, include breakdown products from drugs, environmental pollutants, and

various synthetic compounds. Unclassified breakdown products represent potentially novel

biomarkers, as they have not yet been related to an established metabolic origin. These breakdown

products were noted for their recurring chromatographic and spectral properties and have been

assigned unique COMP-IDs and/or CHEM-IDs (**Supplementary Table S1**), which allows for

identification and comparison in future studies and by other analysis platforms. Genetic associations

with plasma protein values were available from the eight GWAS, detailed in Supplementary Note 1.

Genetic associations with cardiac disease onset were available from Nielsen *et al.* (60,620 AF

cases)(16), from Shah *et al.* (47,309 HF cases)(17), from Garnier *et al.* (2,719 DCM cases)(18), and

from Zhou *et al.* (2,993 HCM cases)(19). Study specific participants characteristics and case/control

definitions are described in Supplementary Note 1. All studies obtained informed consent from

participants and complied with the Declaration of Helsinki.

Mendelian randomisation analyses

Three MR analyses were conducted: 1) genome-wide MR identifying metabolism pathways which, as

reflected by urinary breakdown products, associate with onset of cardiac disease (step 1 **Figure 1,**

Appendix Tables S1, S2), 2) *cis*-MR identifying plasma proteins affecting values of urinary

breakdown products (step 2 **Figure 1**), and 3) *cis*-MR identifying plasma proteins which associate

with the onset of cardiac disease (step 3 **Figure 1**). In the genome-wide MR we selected genetic

variants from across the genome, while in the *cis*-MR genetic variants were selected from a 200

kilobase pair window around and within the protein encoding gene. In both cases, variants were

selected based on an exposure F-statistic of at least 24 and a minor allele frequency of 0.01 or larger.

The remaining variants were clumped to a linkage disequilibrium (LD) r-squared of 0.30, based on a

random 5,000 sample of unrelated UK Biobank participants. The *cis*-MR analyses (steps 2-3 **Figure**

1) were conducted per individual protein GWAS, where the largest sample size GWAS was used in

the case of overlap in measured proteins.

MR analyses were conducted using generalized least squares (GLS) implementations of the inverse

variance weighted (IVW) estimator, as well as the pleiotropy robust MR-Egger estimator[20]. The

GLS implementation was used to additionally correct for residual LD, which optimized estimator

precision[21]. To reduce the potential for horizontal pleiotropy, we excluded variants with large

leverage statistics (larger than three times the mean leverage) and/or outlier statistics (Chi-square

larger than 10.83). Analyses with fewer than 6 variants as instrument were discarded to ensure we had

sufficient data to accurately model the exposure effects. The potential influence of horizontal

pleiotropy was further minimized by applying a model selection framework identifying the MR model

(IVW or MR-Egger) most supported by the available data (Supplementary Note 1).

Effect estimates and multiple testing

MR results are presented as mean differences (MD) for continuous outcomes, or odds ratios (ORs) for

binary outcomes, representing the effect of an SD increase of the exposure (i.e., either urinary

breakdown product or plasma protein value). Effect estimates are not constrained to be positive (i.e.,

they can indicate an increase or decrease in the outcome) and are accompanied by 95% confidence

intervals (CIs) and p-values. Breakdown product effects on disease were filtered for a multiplicity

corrected p-value threshold of $1.37 \times 10^{\square\square}$ based on the 365 principal components that were needed to

explain 90% of the urinary breakdown product variance (**Appendix Figure S1**). Protein MR effect

estimates were evaluated against a multiplicity corrected p-value of 8.42×10^{-7} for the breakdown

products, based on the number of tested proteins (n=1,562) and breakdown products (n=38). The

multiplicity corrected p-value was 1.76×10^{-5} for cardiac outcomes, based on the number of tested

proteins (n=709) and outcomes (n=4). Proteins are referred to using their Uniprot label[22], while

genes are referred to using their Ensembl label in italicised font.

Triangulation of evidence through consideration of concordant cardiac effects

The three distinct MR analyses were integrated by I) identifying urinary breakdown products affecting

cardiac disease, II) identifying whether there were proteins associated with these urinary breakdown

products, and III) focussing on the subset of proteins with a directionally concordant effect on the

same cardiac disease trait the urinary breakdown products associated with. For example, if a higher

value of a urinary breakdown product decreased the risk of HF, and the protein increased the urinary

breakdown product value, the protein effect was considered directionally concordant if in turn higher

protein values decreased HF risk. Conversely, if a higher value of a urinary breakdown product

increased the risk of HF, and the protein decreased the urinary breakdown product value, the protein

effect would still be considered directionally concordant if higher protein values decreased HF risk.

When all these conditions are met – directional concordance between the protein, breakdown product,

and cardiac outcome – we describe this as a triangulated association (**Figure 2**). We note that because

each performed MR analysis makes a distinct, and independent, assumption on the absence of

horizontal pleiotropy, focusing on the directionally concordant results is anticipated to identify a

robust subset of analyses with limited influence of potential horizontal pleiotropy.

Prioritisation of proteins expressed in cardiac tissue

The set of proteins with a triangulated effect on breakdown product and cardiac outcome were

subsequently prioritised for the presence of cardiac tissue mRNA expression, differentiating between

proteins with general cardiac expression, and proteins which were overexpressed (Supplementary Note

1). We also tested for overexpression in other tissues, providing greater context regarding the type of

protein.

Annotation of prioritised proteins

We identified plasma proteins targeted by approved drugs (drugged proteins), as well as potentially

druggable proteins based on ChEMBL-v33. For the drugged and druggable proteins, we additionally

extracted compound indications and side-effects, sourcing information from ChEMBL and the British

National Formulary (BNF, access date September 4, 2021). Finally, all proteins available in the

considered GWAS were mapped to biological pathways using the Reactome knowledgebase-v85(23)

and prioritised proteins (combined irrespective of cardiac or metabolite class association, as well as,

stratified by cardiac disease, or stratified by metabolite class) were tested for enrichment against the

full set of 1,567 proteins.

Partial replication of protein associations with cardiac traits

Due to the availability of 8 proteomics GWAS, some studies assayed the same proteins, which we

leveraged to replicate our findings, specifically focussing on associations with cardiac traits.

Replication was sought using a nominally significant p-value of 0.05 or smaller and considering the

effect direction of the triangulated analysis. In addition, a more stringent p-value threshold of 8.93×10^{-4}

^{4} (0.05 divided by the number of proteins available in more than one study) was used for more

conservative replication.

Results

Urinary breakdown products associating with the onset of cardiac disease

We conducted Mendelian randomisation to identify urinary breakdown products linked to cardiac

disease, unveiling potential non-invasive biomarkers and altered metabolism pathways involved in

cardiac disease progression. Out of 954 evaluated urinary breakdown products (**Appendix Table S1**),

38 breakdown products were found to be associated with at least one type of cardiac disease: 25 for

AF, 11 for HF, 5 for DCM, and 14 for HCM (step 1 **Figure 1**, **Appendix Tables S2, S3, Figure 3**).

Urinary breakdown products were frequently associated with AF, where particularly amino acid and

xenobiotic breakdown products associated with cardiac diseases. For example, higher values of 1-

methylhistamine increased the risk of HF (OR 1.07, 95%CI 1.05; 1.09), while decreasing the risk of

AF (OR 0.83, 95%CI 0.76; 0.90). Higher values of 1-methylxanthine, a xenobiotic breakdown product

of caffeine, decreased the risk of AF, DCM, and HCM (**Appendix Table S2, Figure 3**). Finally, we

were able to associate 16 urinary breakdown products of unknown metabolic origin (unclassified

breakdown products) with cardiac disease.

Triangulated proteins with concordant effects on urinary breakdown products and cardiac

diseases

Mendelian randomisation was used to determine associations between plasma proteins and the 38

urinary breakdown products associated with cardiac disease. We identified 709 proteins associated

with at least one of the 38 urinary breakdown products (step 2 **Figure 1, Appendix Figure S2**). We

then used MR to identify which of these proteins also associated with the considered cardiac diseases

and identified 235 proteins (step 3 **Figure 1, Appendix Figure S3**). By considering directional

concordance and cardiac tissue expression we identified 91 prioritised proteins (step 4 **Figure 1,**

Appendix Tables S4, S5).

This prioritised set included 6 proteins which were overexpressed in cardiac tissues on mRNA level

(**Figure 4**): TIG1 (affecting urinary breakdown products 1-methylxanthine), DNJA4 (affecting urinary

breakdown product X-19141), NAR3 (affecting urinary breakdown products n-acetylcitrulline, 4-

guanidinobutanoate, and X-23776), SPT20 (affecting urinary breakdown products 1-methylhistamine

and X-19141), GLO2 (affecting urinary breakdown products n-methylpipecolate and 3-

hydroxyindolin-2-one sulfate), and PLXA1 (affecting urinary breakdown products 1-methylhistamine,

glycocholenate sulfate, and 1-methylxanthine) (**Appendix Table S4**). Besides their overexpression in

cardiac tissue, these proteins were also overexpressed in at least one other tissue in the body, such as

the skeletal muscle and ovaries (**Appendix Table S4**).

Drugged and druggable prioritised proteins

We sourced ChEMBL and BNF to determine druggability of the prioritised proteins. The set of 91

prioritised proteins included 20 drugged proteins, and 12 druggable proteins (step 4 **Figure 1**). The 20

drugged proteins included seven positive control proteins where the drug indication matched the MR

disease association (ACES, EGLN1, ICAM1, NQO2, RET, TRY3, and UD11). For example, we

showed that higher levels of ACES increased the risk of both AF and HF, mimicking the protective

effect of ACE inhibitor drugs. Furthermore, we identified six proteins targeted by a drug indicated for

a cardiac disease distinct from the MR associations (MANBA, NQO1, NTRK3, OLA1, TEC, and

TRYB1), identifying compounds relevant for rapid drug repositioning. For example, MANBA is

targeted by migalastat used to treat GLA amenable Fabry disease, where the MR analysis supported

potential repositioning to treat AF. Additionally, we identified three proteins (AT1B2, DPEP1, and

MET) targeted by drug compounds with a registered cardiac side-effect which may be relevant for

drug repurposing. Finally, four proteins were targeted by drug compounds without a cardiac indication

or side effect, providing further opportunities for drug repurposing. For example, ADH1B (associated

with HF) is targeted by nitrefazole which is used to treat alcohol addiction (**Table 1, Figure 5,**

Appendix Tables S7, S8).

Irrespective of the known side effects or indications, the identified proteins frequently associated with

AF, with many of these proteins (partially) acting through xenobiotic (n=8) and amino acid (n=6)

metabolism (**Figure 5**). Specifically, GLO2, ACES, EGLN1 (OR 0.88, 95% CI 0.84; 0.92), LYAM2,

IBP3, and ENTP5 affected AF and associated with xenobiotic breakdown product values. Similarly,

DPEP1 (OR 0.97, 95% CI 0.96; 0.98), TRYB1, HEXI1, and TEC (OR 0.87, 95% CI 0.83; 0.90)

affected AF and associated with amino acid breakdown product values. Higher values of TRY3 (OR

0.92, 95% CI 0.90; 0.94) and NAGK decreased AF risk and associated with both amino acid and

xenobiotic breakdown products values.

Most proteins affecting HF associated with unclassified metabolism pathways (n=7). Specifically,

increased values of ACES, RET (OR 0.97, 95% CI 0.96; 0.98), ADH1B, ERAP1 (OR 0.97, 95% CI

0.96; 0.98), FCG2A, NQO1, and CTGF affected HF risk and also associated with unclassified urinary

breakdown products.

Similarly, drugged and druggable proteins affecting HCM predominantly associated with unclassified

metabolism pathways (n=5). Specifically, higher values of ICAM1, NTRK3, CAN2, SIGL7, and

AT1B2 affected HCM risk.

For DCM we identified three drugged or druggable proteins with higher values of UD11 and CATA

increasing DCM risk and associating with peptide breakdown product prolylglycine, and higher values

of PLA2R (OR 0.92, 95% CI 0.91; 0.94) decreasing DCM risk and associating with xenobiotic

breakdown product N-methylpipecolate.

Triangulated proteins with an effect on multiple cardiac traits

We additionally identified eleven pleiotropic proteins associated with multiple cardiac outcomes. Most

of these were associated with unclassified and xenobiotic urinary metabolism breakdown products.

Specifically, ACES, PLXB2, PLXA1, CYTF, and GNPTG affected AF and HF (**Figure 6**). ICAM1,

MICB, and EVA1C affected both HCM and HF, while MATN3 and ACYP2 affected HCM and AF,

while PLA2R affected HCM and DCM (**Figure 6, Appendix Table S6**).

Proteins enriched in biological pathways

Based on the Reactome knowledgebase, we found the "antigen presentation: folding, assembly and

peptide loading of class I MHC" pathway to be enriched among the triangulated proteins. This

pathway involved proteins TPSN (associated with HCM) and ERAP1 (associated with HF)

(**Appendix Tables S6, S9**). Enriched pathways in the subset of prioritised proteins per metabolite

class and per disease outcome are indicated in **Appendix Figure S4** and **S5**.

Replication of protein effects on cardiac outcomes

Of the 91 prioritised proteins associating with one or more cardiac traits 56 were available in more

than a single study, applying a nominal 0.05 p-value threshold this resulted in a replication of 47

(84%) protein associations with cardiac disease. Applying a multiplicity corrected threshold resulted

in 37 (66%) replicated proteins (**Appendix Table S10**). Replication results for protein effects on

breakdown product values are described in Supplementary Note 1 (**Appendix Table S11**).

Discussion

In this study, we used Mendelian randomisation to assess relationships between 954 urinary

breakdown products, 1,562 proteins, and four cardiac diseases AF, HF, DCM, and HCM. We found

directionally concordant associations between 38 breakdown products, 91 cardiac expressed proteins,

and the considered cardiac diseases. The urinary breakdown products are potential biomarkers of

altered metabolism pathways informative of the aetiology and consequences of cardiac diseases, and

the plasma proteins may be used as drug targets to intervene in these metabolism pathways.

The identified urinary breakdown products associating with cardiac disease predominantly included

breakdown products with an origin in amino acids metabolism, xenobiotics metabolism, and of

unclassified metabolism. Of the 91 proteins, six were overexpressed in cardiac tissue. We additionally

identified eleven pleiotropic proteins with an effect on more than one cardiac outcome. Furthermore,

20 proteins were targeted by an approved drug, which included seven positive control proteins that

were targeted by a compound with a cardiac indication matching the MR disease association (ACES,

EGLN1, ICAM1, NQO2, RET, TRY3, and UD11), as well as six targets for drugs with a cardiac

indication distinct from the MR disease association (MANBA, NQO1, NTRK3, OLA1, TEC, and

TRYB1), and three targets for drugs with a known cardiovascular side-effect (AT1B2, DPEP1, and

MET) which may be relevant for drug repurposing. For example, we found that the approved

compounds nitrefazole and arginine may be beneficially repurposed to treat HF or AF, respectively.

Future studies may consider analysis of available (nationwide) prescription data to provide further

evidence of efficacy, which may be confirmed by more time consuming and costly randomised

controlled trials.

We identified seven amino acids breakdown products associated with AF of which six

(cysteinylglycine disulfide, 4-guanidinobutanoate, N-acetylcitrulline, N-acetyl-3-methylhistidine, N-

acetylarginine, and N-acetylasparagine) increased the risk of AF, corroborating previous observations

of altered amino acid metabolism in AF patients(24). We found 27 proteins associated with these

amino acids and AF, including 7 drugged or druggable proteins. For example, we showed that higher

values of MANBA (mannosidase beta) increased AF risk, which is supported by recent GWAS

associating genetic variants near *MANBA* with AF(25) and by two recent MR studies identifying

MANBA as a potential drug target for AF with corresponding effect directions(26, 27). MANBA is

targeted by migalastat, a drug used to treat Fabry disease(28), which closely resembles HCM(29), with

patients often suffering from cardiac arrhythmias and conduction tissue infiltration, leading to

electrical instabilities. An observational study on Fabry disease patients revealed that atrial function

was better preserved in those treated with migalastat compared to untreated individuals(30). Through

our analyses of urinary breakdown products, we were able to link MANBA to fatty acid metabolism

through nonenedioate, with faulty fat metabolism a canonical characteristic of Fabry disease(31).

Jointly, this suggest MANBA may offer therapeutic potential for treatment of AF and related

arrythmias through altered lipid metabolism. These insights not only improve our understanding of the

metabolic origins of atrial fibrillation but also highlight MANBA as a promising target for

intervention. The potential to repurpose migalastat or develop new therapies targeting MANBA offers

a novel approach for AF treatment, potentially relevant in patients with metabolic disturbances similar

to those observed in Fabry disease. Additionally, we found that higher levels of MET are associated

with reduced AF risk. MET is targeted by crizotinib, a cancer drug which has side-effects including

arrythmias. Previous research also identified MET as target with repurposing potential for AF

treatment(32).

We identified eleven urinary breakdown products associating with HF which included five breakdown

products with an origin in amino acids metabolism and five with an unclassified origin. We were able

to map these to 27 plasma proteins with a directionally concordant HF effect, which included MICB

(MHC class I polypeptide-related sequence B). MICB increased the risk of both HF and HCM, and

was linked to seven yet unclassified breakdown products. This closely aligns with our pathway

enrichment analysis identifying MHC class I related pathways implicated in HCM (based on protein

TPSN) and HF (based on protein ERAP1), which are linked to CD8+ T-cell mediated cardiac

remodelling(33), underscoring the potential role of immune modulation in the pathogenesis of these

conditions. While these proteins are not yet druggable, our analysis did identify ICAM1 (associating

with HCM and HF), RET and NQO2 (both associating with HF), which have already been drugged.

Through consideration of urinary breakdown products we were able to associate ICAM1 with 1-

methylxanthine and X-18889, where the former is a breakdown product of xanthine, and the oxidation

of xanthine has been linked to ICAM1 neutrophil binding capacity(34). Notably, immune cell

activation, reflecting systemic but low-grade inflammation, is a likely key pathophysiologic process

progressing towards HCM, other cardiomyopathies, and end-stage HF(35). Regorafenib, a RET

inhibiting drug that is used for cancer treatment, has registered side effects including myocardial

ischemia and hypertension. These side effects support our findings that lower values of RET are

associated with a higher risk of HF onset, where the unclassified urinary breakdown product X-23776

was involved in the triangulated association. The GDNF family receptor α–like (GFRAL) acts a

receptor for GDF15, which signals through the RET co-receptor. GDF15 was found to be relevant for

energy homeostasis and has been identified as a biomarker of cardiovascular and metabolic diseases.

There is potential for a new class of drugs based on GDF15-GFRAL-RET, where the signalling

pathway is modified(36). Additionally, GDF15 has been recognized as an indicator for HF risk and

prediction of hospitalisation for HF or all-cause mortality before(37). The protein NQO2 was

associated with a decreased risk of HF, through the amino acid breakdown product

indoleacetylglutamine. Prazosin, which acts as an adrenergic receptor alpha-1 antagonist and targets

NQO2, has shown potential benefits for HF patients in previous observational studies and trials(38,

39), suggesting prazosin might be a relevant repurposing candidate for HF.

We found five urinary breakdown products and eight proteins associated with DCM risk, including

three drugged or druggable proteins, underscoring their potential clinical relevance. For example, we

showed that increased values of UD11 increased the risk for DCM and reduced the values of the

peptide breakdown product prolylglycine. UD11 is targeted by beta-blockers carvedilol and labetalol

(used for HF, hypertension, coronary artery disease and myocardial ischemia), by the diuretics

furosemide and bumetanide (used for HF and hypertension) and by acetazolamide, which is not used

in practice but has shown benefits in acute decompensated heart failure in a previous clinical trial(40).

These findings suggest that modulation of UD11 could be a viable therapeutic strategy in reducing the

risk of DCM, providing a rationale for further investigation of UD11 as drug target for treatment for

individuals at risk of DCM.

We note that 13 prioritised proteins affected xenobiotic urinary breakdown product values, indicating

that these proteins affect xenobiotic metabolism and excretion. For example, we found that ICAM1

associates with the urinary breakdown product value of xenobiotic 1-methylxanthine. This is in line

with previous findings indicating that increased expression of ICAM1, which is present on the

leukocytes (as well as endothelial cells), facilitates phagocytosis of xenobiotics(41-43).

Despite the robustness of combining multiple MR analyses sourcing various GWAS on both proteins

and breakdown products, there are some potential limitations that we wish to discuss. First of all, the

genetic data we used was sourced from multiple GWAS which used various high throughput assays,

varying in accuracy and analytic scope(44). Instead of directly measuring concentrations, these assays

evaluate relative values of proteins or breakdown products. Hence, the magnitude of association is

difficult to interpret, and potential follow-up studies are needed to explore compound specific

pharmacokinetic and pharmacodynamic properties. Our current analysis predominantly provides

information on the putative drug mechanism and whether compounds should be inhibitory or

activating. In addition, associations between urinary breakdown products and cardiac disease should

not be misinterpreted as implying that urinary breakdown products themselves have a causal effect on

disease. Rather we use urinary breakdown products as a proxy for more distal metabolic processes,

such as those occurring in or impacting cardiac tissue. Due to relying on aggregate data instead of

individual patient data, we could not explore potential influence of variant by environment

interactions, for example due to differences in sex or fasting state. However, genetic variants are

determined at gametogenesis and therefore MR is protected against most forms of confounding

reflecting the presence of a common cause of the genetic variant and the outcome or exposure. Even in

the presence of variant by environment interaction, our triangulation approach prioritises results where

these interactions are either absent or of minimal importance. This makes our approach conservative,

potentially overlooking a number of true associations, but the associations we do identify are robust

against environmental influences, which is also indicated by the high degree of replication.

Furthermore, GWAS data were mainly obtained from European cohorts, which may limit

generalizability to non-European populations. Finally, while we had access to a large sample size

GWAS on HF (47,309 cases), we did not have information on HF subtypes, and future studies

considering HF subtypes may yield additional insights.

Examining the associations between urinary breakdown products, cardiac disease and proteins in a

triangulated way provides a comprehensive and robust analysis. Concordance in results from all three

analyses – which are based on distinct sources of data – indicate a more reliable effect. Discordant

results however do not necessarily indicate invalid MRs but are potentially indicative of a limited

influence of the protein on the metabolism process influencing cardiac disease, or may reflect more

intricate biological processes.

In conclusion, 38 metabolism pathways and 91 proteins were identified for involvement with cardiac

disease, providing important evidence to support drug development of novel and repurposing targets.

Additionally, our manuscript illustrates the value of integrating multi-modal sources of evidence to

identify information potentially relevant for disease diagnosis, prognosis, and aetiology.

Funding: SD and SAEP are supported by a VIDI Fellowship (project number 09150172010050) from

the Dutch Organisation for Health Research and Development (ZonMW) awarded to SAEP. AFS is

supported by BHF grant PG/22/10989, the UCL BHF Research Accelerator AA/18/6/34223,

MR/V033867/1, the National Institute for Health and Care Research University College London

Hospitals Biomedical Research Centre, and the EU Horizon scheme (AI4HF 101080430 and

DataTools4Heart 101057849). This work was supported by the NWO Snellius supercomputer project

(application 2023.022).

Role of funders: The funding source did not influence the study design, the collection, analysis, and

interpretation of data, the writing of the report, or the decision to submit the manuscript for

publication.

Acknowledgements: A preprint version of this manuscript has been deposited at:

https://doi.org/10.1101/2024.02.27.24303421. This research has been conducted using the UK

Biobank Resource under Application Number 12113. The authors are grateful to UK Biobank

participants.

Declaration of competing interests: AFS and CF have received funding from New Amsterdam

Pharma for unrelated projects. The other authors declare that they have no conflict of interest.

Author contributions: SD, AFS, and SP designed the study. SD and MV accessed the data, verified

the data, and performed analyses. SD drafted the manuscript. All authors provided critical input on the

analysis, as well as the drafted manuscript.

Code availability: Analyses were conducted using Python v3.7.13 (for GNU Linux), Pandas v1.3.5,

Numpy v1.21.6, bio-misc v0.1.4, and matplotlib v3.4.3. Code to reproduce figures and tables will be

made available upon publication. Genetic summary-level data underpinning each individual MR

analysis will be made available at Figshare upon publication.

Data availability: The individual GWAS data on cardiac outcomes leveraged in this study can be

accessed as follows: atrial fibrillation (cases=60,620, total n=1,030,836;

https://www.ebi.ac.uk/gwas/publications/30061737), heart failure (cases=47,309, total n=977,323;

https://www.ebi.ac.uk/gwas/publications/31919418), dilated cardiomyopathy (cases=2,719, total

n=6,980; https://www.ebi.ac.uk/gwas/publications/33677556) and hypertrophic cardiomyopathy

(cases=2,993, total n=1,197,200; http://results.globalbiobankmeta.org/pheno/HCM). The GWAS data

on urinary breakdown product values can be accessed via

https://www.ebi.ac.uk/gwas/publications/31959995 (n=1,627). The individual GWAS data on plasma

protein values can be accessed as follows: deCODE (n=35,559,

https://www.decode.com/summarydata/), SCALLOP (n=30,931,

https://www.ebi.ac.uk/gwas/publications/33067605), Ahola-Olli et al. (n=8,293,

https://www.ebi.ac.uk/gwas/publications/27989323), Framingham (n=6,861,

https://www.ebi.ac.uk/gwas/publications/21909115), AGES-Reykjavik (n=5,368,

https://www.ebi.ac.uk/gwas/publications/35078996), INTERVAL (n=3,301,

https://www.ebi.ac.uk/gwas/publications/29875488), Gilly et al. (n=1,328,

https://www.ebi.ac.uk/gwas/publications/33303764), and Yang et al. (n=636,

https://www.ebi.ac.uk/gwas/publications/34239129).

References

1.   Cortés R, Portolés M, Salvador A, Bertomeu V, de Burgos FG, Martínez‐Dolz L, Lletí ER,
Climent V, Jordán A, Payá R. Diagnostic and prognostic value of urine NT‐proBNP levels in heart
failure patients. European journal of heart failure. 2006;8(6):621-7.
2.   Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G,
Pyrgakis V, W Cleman M. NTproBNP: an important biomarker in cardiac diseases. Current topics in
medicinal chemistry. 2013;13(2):82-94.
3.   Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction
in both clinical and forensic medicine. International journal of molecular sciences. 2019;20(8):1820.
4.   Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and
pharmacologic inhibition. Journal of managed care pharmacy. 2007;13(8 Supp B):9-20.
5.   Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K,
Molitch M, Mullens W. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and
treatment strategies: a scientific statement from the American Heart Association. Circulation.
2019;139(16):e840-e78.
6.   Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B,
Chopade S, Faraway R, Zwierzyna M. Genetic drug target validation using Mendelian randomisation.
Nature communications. 2020;11(1):1-12.
7.   Schmidt AF, Hingorani AD, Finan C. Human Genomics and Drug Development. Cold Spring
Harb Perspect Med. 2022;12(2).
8.   Hingorani A, Humphries S. Nature's randomised trials. The Lancet. 2005;366(9501):1906-8.
9.   de Ruiter SC, Schmidt AF, Grobbee DE, den Ruijter HM, Peters SA. Sex-specific Mendelian
randomisation to assess the causality of sex differences in the effects of risk factors and treatment:
Spotlight on hypertension. Journal of Human Hypertension. 2023:1-7.
10.   Cupido AJ, Asselbergs FW, Natarajan P, Group CIW, Ridker PM, Hovingh GK, Schmidt AF.
Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both
IL6 and IL6R. British Journal of Clinical Pharmacology. 2022;88(6):2875-84.
11.   Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P,
Liu Y, Luo S. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome
on complex diseases. Nature genetics. 2020;52(10):1122-31.
12.   Schmidt AF, Hunt NB, Gordillo-Marañón M, Charoen P, Drenos F, Kivimaki M, Lawlor DA,
Giambartolomei C, Papacosta O, Chaturvedi N. Cholesteryl ester transfer protein (CETP) as a drug
target for cardiovascular disease. Nature communications. 2021;12(1):5640.
13.   Consortium I-RMRA. The interleukin-6 receptor as a target for prevention of coronary heart
disease: a mendelian randomisation analysis. The Lancet. 2012;379(9822):1214-24.
14.   Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, van der Laan
SW, Gross C, Clarkson C, Henry A. Druggable proteins influencing cardiac structure and function:
Implications for heart failure therapies and cancer cardiotoxicity. Science Advances.
2023;9(17):eadd4984.
15.   Schlosser P, Li Y, Sekula P, Raffler J, Grundner-Culemann F, Pietzner M, Cheng Y, Wuttke
M, Steinbrenner I, Schultheiss UT. Genetic studies of urinary metabolites illuminate mechanisms of
detoxification and excretion in humans. Nature genetics. 2020;52(2):167-76.
16.   Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, Herron TJ,
McCarthy S, Schmidt EM, Sveinbjornsson G. Biobank-driven genomic discovery yields new insight
into atrial fibrillation biology. Nature genetics. 2018;50(9):1234-9.
17.   Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK, Wilk JB,
Morley MP, Chaffin MD. Genome-wide association and Mendelian randomisation analysis provide
insights into the pathogenesis of heart failure. Nature communications. 2020;11(1):1-12.
18.   Garnier S, Harakalova M, Weiss S, Mokry M, Regitz-Zagrosek V, Hengstenberg C, Cappola
TP, Isnard R, Arbustini E, Cook SA. Genome-wide association analysis in dilated cardiomyopathy
reveals two new players in systolic heart failure on chromosomes 3p25. 1 and 22q11. 23. European
Heart Journal. 2021;42(20):2000-11.

19.   Zhou W, Kanai M, Wu K-HH, Rasheed H, Tsuo K, Hirbo JB, Wang Y, Bhattacharya A, Zhao H, Namba S. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. Cell Genomics. 2022;2(10).

20.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International journal of epidemiology. 2015;44(2):512-25.

21.   Burgess S, Zuber V, Valdes￼Marquez E, Sun BB, Hopewell JC. Mendelian randomization with fine￼mapped genetic data: choosing from large numbers of correlated instrumental variables. Genetic epidemiology. 2017;41(8):714-25.

22.   Consortium U. The universal protein resource (UniProt) in 2010. Nucleic acids research. 2010;38(suppl_1):D142-D8.

23.   Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R. The reactome pathway knowledgebase. Nucleic acids research. 2020;48(D1):D498-D503.

24.   She J, Guo M, Li H, Liu J, Liang X, Liu P, Zhou B, Liu S, Deng Y, Lou B. Targeting amino acids metabolic profile to identify novel metabolic characteristics in atrial fibrillation. Clinical science. 2018;132(19):2135-46.

25.   Miyazawa K, Ito K, Ito M, Zou Z, Kubota M, Nomura S, Matsunaga H, Koyama S, Ieki H, Akiyama M. Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk prediction. Nature genetics. 2023;55(2):187-97.

26.   Wang X, Huang T, Jia J. Proteome￼Wide Mendelian Randomization Analysis Identified Potential Drug Targets for Atrial Fibrillation. Journal of the American Heart Association. 2023;12(16):e029003.

27.   Ning Z, Huang Y, Lu H, Zhou Y, Tu T, Ouyang F, Liu Y, Liu Q. Novel Drug Targets for Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome. Cardiovascular Drugs and Therapy. 2023:1-8.

28.   McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79:543-54.

29.   Moroni A, Tondi L, Milani V, Pieroni M, Pieruzzi F, Bevilacqua F, Pasqualin G, Chow K, Pica S, Lombardi M. Left atrial remodeling in hypertrophic cardiomyopathy and Fabry disease: A CMR-based head-to-head comparison and outcome analysis. International Journal of Cardiology. 2023;393:131357.

30.   Pogoda C, Brand S-M, Duning T, Schmidt-Pogoda A, Sindermann J, Lenders M, Brand E. Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease. Frontiers in Cardiovascular Medicine. 2023;10.

31.   Li X, Ren X, Zhang Y, Ding L, Huo M, Li Q. Fabry disease: Mechanism and therapeutics strategies. Frontiers in Pharmacology. 2022;13:1025740.

32.   Kukendrarajah K, Farmaki A-E, Lambiase PD, Schilling R, Finan C, Schmidt AF, Providencia R. Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies. EBioMedicine. 2024;105.

33.   Komai K, Ito M, Nomura S, Shichino S, Katoh M, Yamada S, Ko T, Iizuka-Koga M, Nakatsukasa H, Yoshimura A. Single-cell analysis revealed the role of CD8+ effector T cells in preventing cardioprotective macrophage differentiation in the early phase of heart failure. Frontiers in Immunology. 2021;12:763647.

34.   Sellak H, Franzini E, Hakim J, Pasquier C. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. 1994.

35.   Lillo R, Graziani F, Franceschi F, Iannaccone G, Massetti M, Olivotto I, Crea F, Liuzzo G. Inflammation across the spectrum of hypertrophic cardiac phenotypes. Heart Failure Reviews. 2023:1-11.

36.   Rochette L, Dogon G, Zeller M, Cottin Y, Vergely C. GDF15 and cardiac cells: current concepts and new insights. International Journal of Molecular Sciences. 2021;22(16):8889.

37.   Bradley J, Schelbert EB, Bonnett LJ, Lewis GA, Lagan J, Orsborne C, Brown PF, Black N, Naish JH, Williams SG. Growth differentiation factor-15 in patients with or at risk of heart failure but before first hospitalisation. Heart. 2023.

38.   Antani J, Antani NJ, Nanivadekar A. Prazosin in chronic congestive heart failure due to ischemic heart disease. Clinical cardiology. 1991;14(6):495-500.

39.	Colucci WS, Wynne J, Holman BL, Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. The American Journal of Cardiology. 1980;45(2):337-44.

40.	Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R. Acetazolamide in acute decompensated heart failure with volume overload. New England Journal of Medicine. 2022;387(13):1185-95.

41.	Zhong H, Lin H, Pang Q, Zhuang J, Liu X, Li X, Liu J, Tang J. Macrophage ICAM-1 functions as a regulator of phagocytosis in LPS induced endotoxemia. Inflammation Research. 2021;70:193-203.

42.	Wen L, Han Z. Identification and validation of xenobiotic metabolism-associated prognostic signature based on five genes to evaluate immune microenvironment in colon cancer. Journal of gastrointestinal oncology. 2021;12(6):2788.

43.	Hubbard AK. Effects of xenobiotics on macrophage function: evaluation in vitro. Methods. 1999;19(1):8-16.

44.	Katz DH, Robbins JM, Deng S, Tahir UA, Bick AG, Pampana A, Yu Z, Ngo D, Benson MD, Chen Z-Z. Proteomic profiling platforms head to head: leveraging genetics and clinical traits to compare aptamer-and antibody-based methods. Science Advances. 2022;8(33):eabm5164.

45.	Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, Gunnarsdottir K, Helgason A, Oddsson A, Halldorsson BV. Large-scale integration of the plasma proteome with genetics and disease. Nature Genetics. 2021;53(12):1712-21.

46.	Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, Page K, Zhernakova DV, Wu Y, Peters J. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature metabolism. 2020;2(10):1135-48.

47.	Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pitkänen N, Lehtimäki T, Kähönen M, Lyytikäinen L-P, Raitoharju E, Seppälä I. Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. The American Journal of Human Genetics. 2017;100(1):40-50.

48.	Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9.

49.	Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ, Lamb JR, Jennings LL, Aspelund T, Emilsson V. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nature communications. 2022;13(1):1-13.

50.	Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73-9.

51.	Gilly A, Park Y-C, Png G, Barysenka A, Fischer I, Bjørnland T, Southam L, Suveges D, Neumeyer S, Rayner NW. Whole-genome sequencing analysis of the cardiometabolic proteome. Nature communications. 2020;11(1):1-9.

52.	Yang C, Farias FH, Ibanez L, Suhy A, Sadler B, Fernandez MV, Wang F, Bradley JL, Eiffert B, Bahena JA. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature neuroscience. 2021;24(9):1302-12.

53.	Rücker G, Schwarzer G, Carpenter JR, Binder H, Schumacher M. Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. Biostatistics. 2011;12(1):122-42.

54.	Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, Karlsson A, Santos R. The druggable genome and support for target identification and validation in drug development. Science translational medicine. 2017;9(383):eaag1166.

Table 1. Positive controls and repurposing opportunities: prioritised proteins affected by approved drug compounds.

PROTEIN	UNIPROT ID	DRUGGABILITY*	METABOLITE CLASS(ES)*	NO. BREAKDOWN PRODUCTS*	BREAKDOWN PRODUCT EFFECT*	CARDIAC EFFECT*	OUTCOME	NO. DRUGS*	CARDIAC INDICATION AND/OR SIDE EFFECT*	CARDIAC INDICATION(S)	CARDIAC SIDE EFFECT(S)	DRUG NAME(S)
ACES	P22303	Drugged	Xenobiotics, Lipid	2	Mixed	1.09 (1.05; 1.13)	AF	23	Yes	Heart failure, Blood pressure disorders	See Appendix Table S7	See Appendix Table S7
ACES			Xenobiotics, Unclassified	2	Mixed	1.06 (1.04; 1.08)	HF					See Appendix Table S7
AT1B2	P14415	Drugged	Unclassified	1	Increasing	0.79 (0.72; 0.87)	HCM	9	Yes	See Appendix Table S7	Arrhythmias, Cardiac conduction disorder	Deslanoside, Digitoxin, Digoxin, Acetyldigitoxin, Istaroxime, Lanatoside c, Omeprazole, Lansoprazole, Pantoprazole
DPEP1	P16444	Drugged	Amino Acid, Unclassified, Peptide	5	Mixed	0.97 (0.96; 0.98)	AF	2	Yes	Endocarditis	See Appendix Table S7	Cilastatin sodium, Cilastatin
EGLN1	Q9GZT9	Drugged	Xenobiotics	1	Increasing	0.88 (0.84; 0.92)	AF	9	Yes	See Appendix Table S7	-	Vadadustat, Enarodustat, Molidustat, Roxadustat, Daprodustat, Oxygen, Ascorbic acid, Citric acid, Fumaric acid
ICAM1	P05362	Drugged	Xenobiotics, Unclassified	2	Mixed	1.10 (1.06; 1.14)	HCM	6	Yes	See Appendix Table S7	-	Enlimomab pegol Bi-505, Enlimomab, Lovastatin, Lifitegrast, Dexamethasone
ICAM1			Xenobiotics	1	Decreasing	1.02 (1.01; 1.03)	HF					Enlimomab pegol Bi-505, Enlimomab, Lovastatin, Lifitegrast, Dexamethasone
MANBA	O00462	Drugged	Lipid	1	Increasing	1.07 (1.06; 1.08)	AF	1	Yes	Fabry disease	-	Migalastat
MET	P08581	Drugged	Peptide	1	Increasing	0.92 (0.88; 0.95)	AF	98	Yes	See Appendix Table S7	Qt interval prolongation, Arrhythmias, Heart failure	See Appendix Table S7
NQO1	P15559	Drugged	Unclassified	1	Increasing	0.97 (0.96; 0.98)	HF	4	Yes	Thrombosis	-	Vatiquinone, Hydrogen peroxide, Dicumarol Menadione
NQO2	P16083	Drugged	Amino Acid	1	Increasing	0.95 (0.93; 0.97)	HF	64	Yes	See Appendix Table S7	-	See Appendix Table S7
NTRK3	Q16288	Drugged	Unclassified	1	Increasing	0.73 (0.65; 0.83)	HCM	38	Yes	Pulmonary hypertension, Blood pressure disorders, Thrombosis	Qt interval prolongation, Heart failure, Blood pressure disorders	See Appendix Table S7
OLA1	Q9NTK5	Drugged	Unclassified	1	Increasing	0.81 (0.77; 0.85)	AF	47	Yes	See Appendix Table S7	-	See Appendix Table S7
RET	P07949	Drugged	Unclassified	1	Decreasing	0.97 (0.96; 0.98)	HF	75	Yes	See Appendix Table S7	Blood pressure disorders, Coronary heart disease	See Appendix Table S7
TEC	P42680	Drugged	Amino Acid	1	Increasing	0.87 (0.83; 0.90)	AF	61	Yes	See Appendix Table S7	-	See Appendix Table S7
TRY3	P35030	Drugged	Xenobiotics, Amino Acid	2	Mixed	0.92 (0.90; 0.94)	AF	15	Yes	See Appendix Table S7	-	See Appendix Table S7
TRYB1	Q15661	Drugged	Amino Acid, Unclassified	2	Increasing	1.02 (1.01; 1.03)	AF	1	Yes	Coronary heart disease, Heart failure, Blood pressure disorders	-	Arginine
UD11	P22309	Drugged	Peptide	1	Decreasing	2.87 (1.97; 4.17)	DCM	76	Yes	See Appendix Table S7	-	See Appendix Table S7
ADH1B	P00326	Drugged	Unclassified	1	Decreasing	1.14 (1.08; 1.20)	HF	2	No	-		Nitrefazole, Fomepizole
CAN2	P17655	Drugged	Unclassified	1	Decreasing	0.57 (0.46; 0.70)	HCM	2	No	-		Bortezomib, Carfilzomib
ENTP5	O75356	Drugged	Xenobiotics	1	Increasing	0.89 (0.86; 0.93)	AF	1	No	-		Anthralin
LYAM2	P16581	Drugged	Xenobiotics	1	Decreasing	1.25 (1.17; 1.33)	AF	4	No	-		Rivipansel, Cdp-850, Uproleselan, Bimosiamose

1
2
N.B. Characteristics of drugged prioritised proteins and urinary breakdown products associated with
one or more cardiac disease(s). Cardiac effect estimates were obtained from *cis* Mendelian
randomisation and are presented as odds ratios representing the effect of a one SD increase in protein
levels, along with corresponding confidence intervals. The breakdown product effect indicates
whether the breakdown product's effect on cardiac disease is risk-increasing or risk-decreasing, based
on *cis* Mendelian randomisation. Druggability was determined based on ChEBML and the British
National Formulary. Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM =
hypertrophic cardiomyopathy, HF = heart failure. More details can be found in Appendix Tables S6,
S7.
12
13

Figure legends (main figures)

Figure 1. Flowchart of the main steps of this study

Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy,

HF = heart failure.

Figure 2. A triangulation diagram illustrating an example of a triangulated association – with directional

concordance – between a protein and its effects on urinary breakdown product values and cardiac disease

N.B. The plus symbol (in red) represents a positive association. The minus symbol (in blue) represents a

negative association (a risk-decreasing effect). Directional concordance is achieved when the direction of effects

aligns consistently, whether increasing or decreasing.

Figure 3. Urinary breakdown products associated with at least one cardiac outcome, presented per

cardiac outcome

N.B. Presented p-values are corresponding to effect estimates obtained from Mendelian randomisation analyses

leveraging genetic data on urinary breakdown products and cardiac diseases. Significant associations after

multiplicity correction are indicated by a star, non-significant associations by a dot. The top row provides the

number of drugged and druggable proteins, sourced from BNF and ChEMBL. Genetic associations with the

cardiac outcomes were obtained from Nielsen *et al*. (60,620 AF cases)(16), from Shah *et al*. (47,309 HF

cases)(17), from Garnier *et al.* (2,719 DCM cases)(18), and from Zhou *et al.* (2,993 HCM cases)(19). Genetic

associations with urinary breakdown products are obtained from Schlosser et al.(n=1,627)(15). For more detailed

information, please refer to the Methods section and **Appendix Table S2**.

Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HCM = hypertrophic cardiomyopathy,

HF = heart failure, MR = Mendelian randomisation.

Figure 4. Cardiac mRNA expression of directionally concordant proteins affecting cardiac disease

presented as percentage of the total expression across all tissues.

N.B. Proteins are identified by their Uniprot label. Proteins displayed in bold font indicate that they are

overexpressed in cardiac tissue compared to non-cardiac tissue. Data were sourced from the Human Protein

Atlas; please refer to the Methods section for more details.

Figure 5. Forest plots of cardiac effects of drugged or druggable prioritised proteins, presented by cardiac

disease

N.B. Point estimates are obtained from Mendelian randomisation analyses leveraging genetic data on plasma

proteins and cardiac diseases. The metabolite classes of the breakdown products affected by the protein and

concordantly associating with the cardiac diseases are indicated on the right y-axis. Genetic associations with the

cardiac outcomes were sourced from Nielsen *et al*. (60,620 AF cases)(16), from Shah *et al*. (47,309 HF

cases)(17), from Garnier *et al*. (2,719 DCM cases)(18), and from Zhou *et al.* (2,993 HCM cases)(19). For a more

detailed description, please refer to the Methods section. Full numerical results can be found in **Appendix**

Tables S6, S7.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HCM =

hypertrophic cardiomyopathy, HF = heart failure, OR = odds ratio.

Figure 6. Forest plot of the cardiac effects of prioritised proteins associating with more than one cardiac

outcome

N.B. Point estimates are obtained from Mendelian randomisation analyses leveraging genetic data on plasma

proteins and cardiac diseases. The metabolite classes of the breakdown products affected by the protein and

concordantly associating with each cardiac disease are indicated on the right y-axis. Genetic associations with

the cardiac outcomes were sourced from Nielsen *et al*. (60,620 AF cases)(16), from Shah *et al*. (47,309 HF

cases)(17), from Garnier *et al*. (2,719 DCM cases)(18), and from Zhou *et al.* (2,993 HCM cases)(19). For a more

detailed description, please refer to the Methods section. Full numerical results can be found in **Appendix Table**

S6.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HCM =

hypertrophic cardiomyopathy, HF = heart failure, OR = odds ratio.

Step 1
Genome-wide MR

Urinary breakdown products
(n = 954)

Schlosser et al. (n = 1,627)

Cardiac outcomes:
AF, HF, DCM, HCM

AF: Nielsen et al. (60,620 cases)   DCM: Garnier et al. (2,719 cases)
HF: Shah et al. (47,309 cases)   HCM: Zhou et al. (2,993 cases)

Step 2
Cis-MR on urinary breakdown products

Unique urinary breakdown products associated with cardiac outcome
(n = 38)

Proteins
(n = 1,562 unique proteins)

deCODE (n = 35,559)   AGES-Reykjavik (n = 5,368)
SCALLOP (n = 30,931)   INTERVAL (n = 3,301)
Ahola-Olli et al. (n = 8,293)   Gilly et al. (n = 1,328)
Framingham (n = 6,861)   Yang et al. (n = 636)

Step 3
Cis-MR on cardiac outcomes

Cardiac outcomes:
AF, HF, DCM, HCM

Proteins associated with a cardiac urinary breakdown product
(n = 709)

Step 4
Prioritising on concordance in direction, cardiac expression and druggability

Unique proteins associated with both a cardiac urinary breakdown product and cardiac outcome
(n = 235)

Unique proteins with a directionally concordant association with both a urinary breakdown product and cardiac outcome, expressed in cardiac tissue
(n = 91)

Drugged proteins
(n = 20)

Druggable proteins
(n = 12)

Not yet druggable proteins
(n = 59)

Percentage of total RNA expression in cardiac tissue